XML 33 R24.htm IDEA: XBRL DOCUMENT
v3.23.1

Segment Data (Tables) | 6 Months Ended
--- | ---
Mar. 31, 2023
Segment Reporting [Abstract] |
Revenue from External Customers by Geographic Area | Revenues by segment, organizational unit and geographical areas for the three and six-month periods are detailed below. The Company has no material intersegment revenues.
| Three Months Ended March 31,
(Millions of dollars) | 2023 |  | 2022
| United States |  | International |  | Total |  | United States |  | International |  | Total
Medical |  |  |  |  |  |  |  |  |  |  |
Medication Delivery Solutions (a) | $ | 616 |  |  | $ | 454 |  |  | $ | 1,070 |  |  | $ | 590 |  |  | $ | 460 |  |  | $ | 1,049 |
Medication Management Solutions | 550 |  |  | 173 |  |  | 723 |  |  | 461 |  |  | 143 |  |  | 604 |
Pharmaceutical Systems (a) | 173 |  |  | 394 |  |  | 567 |  |  | 125 |  |  | 375 |  |  | 501 |
Total segment revenues | $ | 1,339 |  |  | $ | 1,022 |  |  | $ | 2,360 |  |  | $ | 1,176 |  |  | $ | 978 |  |  | $ | 2,154 |
Life Sciences |  |  |  |  |  |  |  |  |  |  |
Integrated Diagnostic Solutions | $ | 422 |  |  | $ | 466 |  |  | $ | 888 |  |  | $ | 618 |  |  | $ | 532 |  |  | $ | 1,150 |
Biosciences | 159 |  |  | 228 |  |  | 386 |  |  | 129 |  |  | 206 |  |  | 335 |
Total segment revenues | $ | 581 |  |  | $ | 694 |  |  | $ | 1,275 |  |  | $ | 747 |  |  | $ | 738 |  |  | $ | 1,485 |
Interventional |  |  |  |  |  |  |  |  |  |  |
Surgery | $ | 295 |  |  | $ | 86 |  |  | $ | 381 |  |  | $ | 268 |  |  | $ | 72 |  |  | $ | 340 |
Peripheral Intervention | 256 |  |  | 213 |  |  | 468 |  |  | 240 |  |  | 210 |  |  | 450 |
Urology and Critical Care | 263 |  |  | 74 |  |  | 336 |  |  | 239 |  |  | 82 |  |  | 320 |
Total segment revenues | $ | 813 |  |  | $ | 373 |  |  | $ | 1,186 |  |  | $ | 746 |  |  | $ | 364 |  |  | $ | 1,111 |
Total revenues from continuing operations | $ | 2,733 |  |  | $ | 2,088 |  |  | $ | 4,821 |  |  | $ | 2,669 |  |  | $ | 2,081 |  |  | $ | 4,750 |
(a)Certain prior-period amounts were recast to reflect former intercompany transactions with Embecta.
| Six Months Ended March 31,
(Millions of dollars) | 2023 |  | 2022
| United States |  | International |  | Total |  | United States |  | International |  | Total
Medical |  |  |  |  |  |  |  |  |  |  |
Medication Delivery Solutions (a) | $ | 1,235 |  |  | $ | 873 |  |  | $ | 2,109 |  |  | $ | 1,210 |  |  | $ | 936 |  |  | $ | 2,146 |
Medication Management Solutions | 1,114 |  |  | 316 |  |  | 1,430 |  |  | 945 |  |  | 286 |  |  | 1,231 |
Pharmaceutical Systems (a) | 292 |  |  | 684 |  |  | 976 |  |  | 228 |  |  | 669 |  |  | 897 |
Total segment revenues | $ | 2,642 |  |  | $ | 1,873 |  |  | $ | 4,515 |  |  | $ | 2,383 |  |  | $ | 1,892 |  |  | $ | 4,274 |
Life Sciences |  |  |  |  |  |  |  |  |  |  |
Integrated Diagnostic Solutions | $ | 930 |  |  | $ | 911 |  |  | $ | 1,841 |  |  | $ | 1,232 |  |  | $ | 1,062 |  |  | $ | 2,295 |
Biosciences | 296 |  |  | 440 |  |  | 736 |  |  | 258 |  |  | 416 |  |  | 674 |
Total segment revenues | $ | 1,226 |  |  | $ | 1,351 |  |  | $ | 2,577 |  |  | $ | 1,490 |  |  | $ | 1,478 |  |  | $ | 2,968 |
Interventional |  |  |  |  |  |  |  |  |  |  |
Surgery | $ | 582 |  |  | $ | 162 |  |  | $ | 744 |  |  | $ | 549 |  |  | $ | 152 |  |  | $ | 701 |
Peripheral Intervention | 492 |  |  | 410 |  |  | 902 |  |  | 457 |  |  | 407 |  |  | 863 |
Urology and Critical Care | 522 |  |  | 148 |  |  | 670 |  |  | 492 |  |  | 168 |  |  | 661 |
Total segment revenues | $ | 1,595 |  |  | $ | 720 |  |  | $ | 2,315 |  |  | $ | 1,498 |  |  | $ | 727 |  |  | $ | 2,225 |
Total Company revenues from continuing operations | $ | 5,462 |  |  | $ | 3,944 |  |  | $ | 9,407 |  |  | $ | 5,372 |  |  | $ | 4,096 |  |  | $ | 9,468 |
(a)Certain prior-period amounts were recast to reflect former intercompany transactions with Embecta.
Financial Information for Company's Segments | Segment income for the three and six-month periods was as follows:
| Three Months Ended March 31, |  | Six Months Ended March 31,
(Millions of dollars) | 2023 |  | 2022 |  | 2023 |  | 2022
Income from Continuing Operations Before Income Taxes |  |  |  |  |  |  |
Medical (a) | $ | 641 |  |  | $ | 476 |  |  | $ | 1,195 |  |  | $ | 1,048 |
Life Sciences | 394 |  |  | 475 |  |  | 827 |  |  | 1,009 |
Interventional | 297 |  |  | 280 |  |  | 598 |  |  | 544 |
Total Segment Operating Income | 1,333 |  |  | 1,231 |  |  | 2,621 |  |  | 2,602 |
Acquisition-related integration and restructuring expense | (62) |  |  | (28) |  |  | (106) |  |  | (62) |
Net interest expense | (108) |  |  | (95) |  |  | (204) |  |  | (191) |
Other unallocated items (b) | (635) |  |  | (665) |  |  | (1,301) |  |  | (1,307) |
Total Income from Continuing Operations Before Income Taxes | $ | 529 |  |  | $ | 442 |  |  | $ | 1,009 |  |  | $ | 1,041 |
(a)The amounts for the three and six months ended March 31, 2022 include a charge of $54 million recorded to Cost of products sold to write down the carrying value of certain fixed assets in the Pharmaceutical Systems unit, as well as a charge of $35 million to adjust estimated future product remediation costs. (b)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph a -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration